Literature DB >> 22120206

Obesity, inflammation, and liver cancer.

Beicheng Sun1, Michael Karin.   

Abstract

Obesity has become a universal and major public health problem with increasing prevalence in both adults and children in the 21st century, even in developing countries. Extensive epidemiological studies reveal a strong link between obesity and development and progression of various types of cancers. The connection between obesity and liver cancer is particularly strong and obesity often results in liver diseases such as non-alcoholic fatty liver disease (NAFLD) and the more severe non-alcoholic steatohepatitis (NASH). NASH is characterized by fatty liver inflammation and is believed to cause fibrosis and cirrhosis. The latter is a known liver cancer risk factor. In fact due to its much higher prevalence obesity may be a more substantial contributor to overall hepatocellular carcinoma burden than infection with hepatitis viruses. Here we review and discuss recent advances in elucidation of cellular and molecular alterations and signaling pathways associated with obesity and liver inflammation and their contribution to hepatocarcinogenesis.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22120206      PMCID: PMC3889660          DOI: 10.1016/j.jhep.2011.09.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  151 in total

1.  Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men.

Authors:  Marie-Hélène Gannagé-Yared; Simon Khalife; Michelle Semaan; Florence Fares; Selim Jambart; Georges Halaby
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

Review 2.  Selective autophagy in cancer development and therapy.

Authors:  Ivan Dikic; Terje Johansen; Vladimir Kirkin
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 3.  Hepatic complications of obesity.

Authors:  Anna Mae Diehl
Journal:  Gastroenterol Clin North Am       Date:  2010-03       Impact factor: 3.806

4.  Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

Authors:  Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

Review 5.  Inflammation meets cancer, with NF-κB as the matchmaker.

Authors:  Yinon Ben-Neriah; Michael Karin
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

Review 6.  Metformin and cancer: new applications for an old drug.

Authors:  Taxiarchis V Kourelis; Robert D Siegel
Journal:  Med Oncol       Date:  2011-02-08       Impact factor: 3.064

7.  Nuclear damage in peripheral lymphocytes of obese and overweight Italian children as evaluated by the gamma-H2AX focus assay and micronucleus test.

Authors:  Roberto Scarpato; Carmela Verola; Barbara Fabiani; Vanessa Bianchi; Giuseppe Saggese; Giovanni Federico
Journal:  FASEB J       Date:  2010-11-10       Impact factor: 5.191

Review 8.  Obesity and inflammation in children.

Authors:  Sarah Jane Schwarzenberg; Alan R Sinaiko
Journal:  Paediatr Respir Rev       Date:  2006-10-12       Impact factor: 2.726

9.  CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.

Authors:  Satoshi Nishimura; Ichiro Manabe; Mika Nagasaki; Koji Eto; Hiroshi Yamashita; Mitsuru Ohsugi; Makoto Otsu; Kazuo Hara; Kohjiro Ueki; Seiryo Sugiura; Kotaro Yoshimura; Takashi Kadowaki; Ryozo Nagai
Journal:  Nat Med       Date:  2009-07-26       Impact factor: 53.440

10.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

View more
  183 in total

1.  Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines.

Authors:  Rajesh Narasimamurthy; Megumi Hatori; Surendra K Nayak; Fei Liu; Satchidananda Panda; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease.

Authors:  Hyunjoo Kwon; Kyoungsub Song; Chang Han; Weina Chen; Ying Wang; Srikanta Dash; Kyu Lim; Tong Wu
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

Review 3.  Treating liver cancer with antibiotics?

Authors:  Hui Mao; Xue-zhu Feng; Shou-hong Guang
Journal:  Acta Pharmacol Sin       Date:  2013-08       Impact factor: 6.150

Review 4.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

Review 5.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

Review 6.  Obesity and cancer: A mechanistic overview of metabolic changes in obesity that impact genetic instability.

Authors:  Pallavi Kompella; Karen M Vasquez
Journal:  Mol Carcinog       Date:  2019-06-05       Impact factor: 4.784

7.  New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance.

Authors:  Ngoc Lan Tran; Giovanni Sitia
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

8.  Comparison of silver nanoparticle-induced inflammatory responses between healthy and metabolic syndrome mouse models.

Authors:  Lisa Kobos; Saeed Alqahtani; Li Xia; Vincent Coltellino; Riley Kishman; Daniel McIlrath; Carlos Perez-Torres; Jonathan Shannahan
Journal:  J Toxicol Environ Health A       Date:  2020-04-12

Review 9.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

10.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.